



Helmut Schütz, BEng

Neubaugasse 36/11
 1070 Vienna, Austria
 T +43 (0)1 231 17 46
 M +43 (0)699 107 924 58
 E helmut.schuetz@bebac.at

Personal Details

Nationality: Austrian
 Age: 60
 Place of Birth: Vienna

Education

1974 – 1979

Secondary College for Chemical Engineering

Vienna

Educational Focus: Technical Chemistry, Final Examination passed with Distinction.
 Degree 'Ingenieur' (Chemical Engineer).

1983

Language Skills

Native German, fluent in spoken and written English.

Activities

1980 – 1981

Gerot Pharmazeutika GesmbH

Vienna

Syntheses of NCEs (β -Blockers, Benzodiazepines).

1981 – 1984

Pharmakologische Untersuchungsgesellschaft mbH

Vienna

Trace Analysis (GC/HPLC).

Development of Software, Evaluation of Bioequivalence and Pharmacokinetic Studies.

1984 – 2004

Biokinet GmbH

Vienna

Manager of the Analytical Laboratory.

Development and Validation of Analytical Methods for the Determination of Drugs in Biological Matrices.

1984 – 1987

1987 – 2004

Manager of the Department of Biostatistics and Data Management.

Design, Implementation, Administration of a Laboratory Information Management System (LIMS) according to the Rules of GLP (Good Laboratory Practices).

Design and Evaluation of more than 500 Phase I Studies.

Assessment of about 50 Phase I Studies of external Contract Research Organizations (CROs).

2004 – current

BEBAC

Consultancy Services for Bioequivalence and Bioavailability Studies

Vienna

Independent Consultant in the Domain of Bioavailability and Bioequivalence Studies.

Biostatistical Services (Design, Evaluation and Assessment of Studies; Lectures, Workshops).

Contractor Selection and Supervision, Support at Regulatory Meetings.

Administrator of the BE/BA Internet Forum.

Memberships

1992 – 2014

DIA Drug Information Association

2004 +

WKO Wirtschaftskammer Österreichs (The Austrian Federal Economic Chamber)

2004 +

FI Fachverband Ingenieurbüros (Austrian Association of Consulting Engineers)

2005 +

ROeS Region Austria-Switzerland of the IBS (International Biometric Society)

2005 +

ÖPhG Österreichische Pharmazeutische Gesellschaft (Austrian Pharmaceutical Association)

2005 +

ENBIS European Network for Business and Industrial Statistics

2010 +

FIP International Pharmaceutical Federation

2014 +
2015 +
2015 +

AAPS American Association of Pharmaceutical Scientists
EUFEPS European Federation for Pharmaceutical Sciences
Editorial Board of *Drugs in R&D*.

IT-Proficiency

Operating Systems: UNIX-HP/UX [Hewlett Packard], DOS [M\$], M\$-Windows [XP/Vista/Win7]
Networks: LanManager [HP, M\$], Samba [GNU]
GUIs: CDE [HP], M\$-Windows [v3.11/NT4/2000]
Scripts/Macros: Awk, C-Shell [Unix], BAT, Access, Excel [M\$], JavaScript [Sun]
Languages: BASIC-Dialects (Rocky Mountain Basic [HP], HTB [TransEra], GWBasic/QuickBasic/VBA [M\$], CRA-Basic [Shimadzu]), Pascal for Workstations [HP], TurboPascal [Borland]
Web: (X)HTML, CSS, Apache [GNU], PHP [GNU]
Databases: dBase [Ashton-Tate], ACCESS [M\$], MySQL [Oracle]
LIMS: LAB-UX [HP/Agilent Technologies]
Software: BioEvaluat (Biokinet), Statistica (StatSoft), StatXact (Cyxel), Phoenix|WinNonlin/NLME (Certara Pharsight), EquivTest/PK (Statistical Solutions), MONOLIX (The Monolix Group), NCSS (NCSS Software), StudySize/Result (CreoSoft), TOPFIT (Springer), Kinetica (Thermo Scientific), WinBUGS / PKBugs (GNU), Berkley Madonna (Macey & Oster), BIOEQV (Wijnand), Boomer (Bourne), WinSAAM (WinSAAM Inc), R (The R Foundation for Statistical Computing), Acrobat (Adobe), Office (M\$, Apache), ...

Presentations / Continuing Education

Derivatization in GC (🇦🇹 Vienna 1982)
Bioavailability/Bioequivalence, Pharmaceutical and Therapeutic Equivalence (🇩🇪 Würzburg 1987)
European Congress of Biopharmaceutics and Pharmacokinetics (🇩🇪 Freiburg 1987, 🇨🇭 Geneva 1990, 🇧🇪 Brussels 1993)
Forum Analytik (🇦🇹 Vienna 1988, 1989, 1991, 1992, 1993)
International Symposium on Coupled Column Separation (🇸🇪 Uppsala 1988)
Background – Design – Analysis & Interpretation of Bioavailability / Bioequivalence Studies (🇬🇧 London 1990)
Bioavailability and Pharmacokinetics (🇳🇱 Amsterdam 1990)
Modern Methods for Drug Monitoring and their Impact on Clinical Practice (🇦🇹 Graz 1990)
Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies Conference (🇺🇸 Arlington 1990)
Workshop in Pharmacokinetic Modeling (🇺🇸 Palo Alto 1991)
Workshop in Bioavailability/Bioequivalence (🇺🇸 Palo Alto 1991)
LIMS Workshop (🇦🇹 Linz 1992)
International Open Conference on Dissolution, Bioavailability, Bioequivalence (🇨🇦 Toronto 1992)
Oral Modified-Release Dosage Forms: Biopharmaceutical Challenges and Clinical Implications (🇸🇪 Stockholm 1992)
Computerized Data Handling – Current Trends in Pharmaceutical and Clinical Research (🇩🇪 Neu-Ulm 1993)
Bio-International Conference (🇩🇪 Munich 1994, 🇬🇧 London 1999, 2003, 2005, 2008)
Dissolution Testing, Bioequivalence & Bioavailability Studies (🇧🇪 Brussels 2004)
Dissolution, Bioavailability & Bioequivalence (🇳🇱 Amsterdam 2005)
Dissolution Testing, Bioavailability & Bioequivalence (🇭🇺 Budapest 2006, 2007, 🇩🇪 Berlin 2007)
International Regulatory Workshop on Bioequivalence and Dissolution (🇭🇺 Budapest 2006)
EGA Workshop on Bioequivalence Study Design, Working to GCP and Interpreting the Guidelines (🇵🇹 Lisbon 2007)
Dissolution, Bioavailability and Bioequivalence (🇭🇺 Budapest 2008, 🇨🇪 Prague 2008)
Dissolution Testing, Bioequivalence and Bioavailability Strategies (🇬🇧 London 2008)
Increasing Predictability in Gastrointestinal Simulation (🇩🇪 Zeist 2008)
Second World Conference on Magic Bullets – Ehrlich II (🇩🇪 Nuremberg 2008)
CMD(h)-EGA Symposia on Bioequivalence (🇫🇷 Paris 2008, 🇬🇧 London 2010)
Bioavailability, Bioequivalence, Pharmacokinetics & Beyond (🇮🇳 Ahmedabad 2008)
EUFEPS BABP Open Discussion Forum (🇩🇪 Bonn 2009, 🇪🇸 Barcelona 2011)
Bioequivalence and Bioavailability (🇭🇺 Budapest 2009, 🇸🇮 Ljubljana 2010)
Introduction to Phoenix WinNonlin 6.0 (🇩🇪 Munich 2009)
EBF & EUFEPS Workshop: EMEA Draft Guideline on Validation of Bioanalytical Methods (🇧🇪 Brussels 2010)
International Regulatory Workshops on Bioequivalence, Bioanalysis, Dissolution and Biosimilarity (🇭🇺 Budapest 2010, 2012, 2014)
Bioequivalence and Bioavailability Studies (🇩🇪 Munich 2010, 🇧🇪 Brussels 2011)
Biostatistics: Basic concepts & applicable principles for various designs in bioequivalence studies and data analysis (🇮🇳 Mumbai 2011)

Bioavailability/Bioequivalence and Dissolution Testing (🇹🇷 Budapest 2011)
 International Symposium on BA/BE of Oral Drug Products (🇯🇵 Kobe 2011)
 Innovations in Modified Release (🇩🇪 Berlin 2011)
In vitro in vivo Correlation (IVIVC), Biowaivers & Statistical Aspects of Bioequivalence in Drug Product Development (🇮🇳 Mumbai 2012)
 Drug development and registration «Pharma-2020» Implementation Strategy (🇷🇺 Moscow 2012)
 Advanced concepts of IVIVC through case studies; Biostatistical aspects of Reference-scaled & Two stage designs (🇮🇳 Mumbai 2013)
 Bioavailability / Bioequivalence, Dissolution and Biowaivers (🇹🇷 Budapest 2013, 2014, 🇨🇪 Prague 2015)
 EUFEPS BABP Open Discussion Forum on the Revised European Guideline on Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms (🇩🇪 Bonn 2013)
 Bioequivalence Assessment of Oral Dosage Forms (🇮🇧 Leuven 2013)
 MENA Regulatory Conference on Bioequivalence, Biowaiver, Bioanalysis and Dissolution (🇸🇦 Amman 2013, 2018)
 5th BBBB International Conference. From Drug Discovery and Formulation Strategies to Pharmacokinetics and Pharmacodynamics (🇬🇷 Athens 2013)
 Clinical Development Workshop (🇨🇪 Prague 2013)
 Haemophilia Master Class: Personalized Treatment and Care (🇩🇪 Munich 2014, 🇩🇪 Frankfurt 2014)
 Innovative Statistical Approaches in Drug Development (🇦🇹 Vienna 2014)
 Spanish Congress of Pharmacy and Pharmaceutical Technology (🇪🇸 Barcelona 2015)
 Interaktiver Workshop PK-Dosing in der Hämophilie A (🇩🇪 Munich 2015)
 EUFEPS BABP Network: Global Bioequivalence Harmonisation Initiative (🇳🇱 Amsterdam 2015, 🇺🇸 Rockville 2016, 🇳🇱 Amsterdam 2018)
 EMA / EGA joint workshop on the impact of the revised EMA Guideline on the Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Form (🇬🇧 London 2015)
 International Symposium on Scientific and Regulatory Advances in Complex Drugs (🇹🇷 Budapest 2015, 2016, 2018)
 5th Scientific Conference “Clinical Trials of Medicines in Ukraine” (🇺🇦 Kiev 2015)
 Scientific and Regulatory Issues in Drug Development and Bioequivalence (🇵🇹 Lisbon 2016)
 25th PAGE meeting (🇵🇹 Lisbon 2016)
 To New Shores in Drug Development Implementing Statistical Innovation (🇦🇹 Vienna 2016)
 BA/BE Workshop (🇨🇪 Prague 2016)
 BE Workshop (🇷🇺 Moscow 2016)
 BioBridges (🇨🇪 Prague 2017, 2018)
 Annual Biosimilars Forum (🇹🇷 Budapest 2017, 2018)
 11th International Conference «Studies of medicinal products: Simple and complex tasks» (🇷🇺 Yaroslavl 2017)

Workshops / in-house Trainings

Regulatory Update and Overview of BE and BA Testing with an Industry Perspective (🇹🇷 Istanbul 2006)
 Bioequivalence (🇨🇮 Aesch 2008, 2011, 🇳🇱 Nijmegen 2010, 🇸🇮 Ljubljana 2010, 🇩🇪 Munich 2010, 🇩🇪 Holzkirchen 2010, 🇦🇹 Vienna 2011, 🇨🇭 Nyon 2012, 🇷🇺 Bucharest 2013, 🇱🇹 Kaunas 2017)
 Workshop on Statistics for Bioequivalence Studies (🇨🇪 Prague 2009, 🇷🇺 Moscow 2012)
 Design and Interpretation of Bioequivalence Studies – Current and Future Issues (🇩🇪 Berlin 2010)
 Workshop on Bioanalytics (🇨🇪 Prague 2010)
 Advanced training on pharmacokinetics, statistics and analytics in Bioequivalence Studies in Russia (🇷🇺 Moscow 2012, 2014)
 Seminar on BE Studies (🇨🇪 Prague 2012)
 Workshop in Biostatistics for Bioequivalence (🇩🇪 Ulm 2013, 🇭🇷 Zagreb 2013)
 Design and Evaluation of Bioequivalence Studies (🇪🇸 Barcelona 2014)
 PK–NCA, PK based Design, Biostatistics (🇨🇪 Prague 2015)
 Drug Modeling & Consulting (🇪🇸 Bilbao 2016)
 Bioequivalence, Dissolution & IVIVC (🇩🇪 Berlin 2016, 🇪🇸 Barcelona 2017, 🇦🇹 Vienna 2017, 🇪🇸 León 2017, 🇪🇸 Barcelona 2018, 🇬🇷 Athens 2018)
 Inflation of the Type I Error in Reference-scaled Average Bioequivalence (🇦🇹 Vienna 2016, 🇨🇪 Prague 2016)
 Course on Pharmacokinetics and Bioequivalence (🇹🇷 Budapest 2017)
 Open Issues in the Assessment of Bioequivalence and Biosimilarity (🇹🇷 Budapest 2017)
 Bioequivalence (🇱🇹 Kaunas 2017)
 Basic Statistical Concepts behind BE Testing (🇪🇸 Pamplona 2018)
 Introduction into Basic Principles of Pharmacokinetics (🇩🇪 Oberursel 2018)

Posters

- Eichinger A, Schütz H, Nitsche V. *Development and Application of an HPLC Determination of Buspirone in Plasma by Solid-Phase Extraction and On-Line Precolumn Trace Enrichment*. International Symposium on Coupled Column Separations, Uppsala, Sweden; 1988, October 26–27: Poster 7.
- Eichinger A, Schütz H, Nitsche V. *Determination of Buspirone in Plasma by HPLC with Solid-Phase Extraction and On-Line Precolumn Trace Enrichment and its Application to a Pharmacokinetic Study*. 4th European Congress of Biopharmaceutics and Pharmacokinetics, Geneva, Switzerland; 1990, April 17–19. *Europ J Drug Metabol Pharmacokin*. 1990;15(1):P234.
- Schütz H, Eichinger A, Nitsche V. *Determination of Amoxicillin and Ampicillin using a new HPLC Method with Post-Column Derivatization and its Application to Bioavailability Studies*. 4th European Congress of Biopharmaceutics and Pharmacokinetics, Geneva, Switzerland; 1990, April 17–19. *Europ J Drug Metabol Pharmacokin*. 1990;15(1):P235.
- Schütz H, Eichinger A, Krenauer J, Wolf C, Nitsche V. *Implementierung der GLP in einem Auftragsforschungslabor mit 6 Mitarbeitern*. 10. Forum Analytik, Vienna, Austria; 1993, January 25–27.
- Henry A, Schütz H, Hughes L, Davis S. *Performing Reference-Scaled Average Bioequivalence (RSABE) in Phoenix[®] WinNonlin[®]*. AAPS Annual Meeting and Exposition, San Antonio, TX; 2013, November 10–14: Poster T2350. doi:10.13140/RG.2.1.1008.0800.
- König F, Wolfsegger MJ, Jaki T, Schütz H, Wassmer G. *Adaptive two-stage bioequivalence trials with early stopping and sample size re-estimation*. 35th Annual Conference of the International Society for Clinical Biostatistics, Vienna, Austria; 2014, August 24–28: Poster P1.2.88. doi:10.13140/RG.2.1.5190.0967.
- König F, Wolfsegger MJ, Jaki T, Schütz H, Wassmer G. *Adaptive two-stage bioequivalence trials with early stopping and sample size re-estimation*. 3rd International Clinical Trials Methodology Conference, Glasgow, UK; 2015, November 16–17: Poster 218. *Trials* 16(Suppl 2):P218. doi:10.1186/1745-6215-16-S2-P218.
- Booth J, Schütz H, Steinitz-Trost K, Lee H-Y, Bauer A, Wolfsegger M. *An investigation of the minimum half-life extension needed to make a clinically meaningful impact on dosing frequency of extended half-life recombinant FVIII products*. XXVI Congress of the International Society on Thrombosis and Haemostasis and 63rd Annual Scientific and Standardization Committee (SSC) Meeting, Berlin, Germany; 2017, July 8–13: PB 1131.
- Booth J, Schütz H, Steinitz-Trost K, Lee H-Y, Bauer A, Wolfsegger M. *Minimum half-life extension ratio model for reduced dosing frequency of extended half-life recombinant FVIII products*. HAA Annual Scientific Meeting, Sydney, Australia; 2017, October 29–November 01: P223.
- Mehl C, Henry A, Hughes L, Schütz H. *Reference-Scaled Average Bioequivalence (RSABE) Approach For Compounds With A Narrow Therapeutic Index (NTID) Using Phoenix[™] WinNonlin[®]*. AAPS Annual Meeting and Exposition, San Diego, CA; 2017, November 12–16: Poster W2087. doi:10.13140/RG.2.2.35361.30564.
- Booth J, Schütz H, Steinitz-Trost K, Lee H-Y, Bauer A, Wolfsegger M. *A Model of the Minimum Half-life Extension Ratio Needed to Reduce the Dosing Frequency of Extended Half-life (EHL) Recombinant FVIII (rFVIII) Products*. 62nd Annual Meeting of the Society of Thrombosis and Haemostasis Research, Vienna, Austria; 2018, February 20–23: P160.

Papers

- Nitsche V, Mascher H, Schütz H. *Comparative bioavailability of several phenytoin preparations marketed in Austria*. *Int J Clin Pharm Ther Toxicol*. 1984;22(2):104–7. PMID 6698663.
- Mascher H, Nitsche V, Schütz H. *Separation, Isolation and Identification of Optical Isomers of 1,4-Benzodiazepine Glucuronides from Biological Fluids by Reversed-Phase High-Performance Liquid Chromatography*. *J Chromatogr, Biomed Appl*. 1984;306:231–9. PMID 6715462.
- Nitsche V, Mascher H, Schütz H. *Bioverfügbarkeit von Amilorid-Hydrochlorothiazid-Kombinationspräparaten*. *Therapiewoche*. 1985;36:56–60.
- Nitsche V, Schütz H, Eichinger A. *Rapid high-performance liquid chromatographic determination of nifedipine in plasma with on-line precolumn solid-phase extraction*. *J Chromatogr, Biomed Appl*. 1987;420:207–11. PMID 3667823.
- Nitsche V, Lauschner R, Eichinger A, Schütz H. *Absolute Bioverfügbarkeit von Ambroxol-Zäpfchen*. *Pharm Ztg*. 1988;32:28–33.
- Schütz H, Eichinger A, Nitsche V, Hofmann R. *Relative bioavailability of 3 different chlormezanone 200 mg preparations after single dose oral administration*. *Int J Clin Pharm Ther*. 1997;35(3):112–6. PMID 9089000.
- Bohner H, Janiak PS, Nitsche V, Eichinger A, Schütz H. *Relative bioavailability of different butamirata citrate preparations after single dose oral administration to 18 healthy volunteers*. *Int J Clin Pharm Ther*. 1997;35(3):117–22. PMID 9089001.
- Schütz H. *An extremely strange observation?* [letter]. *Europ J Drug Metabol Pharmacokin*. 2004;29(1):69–71. PMID 15151173.
- Fischer R, Schütz H, Grossmann M, Leis HJ, Ammer R. *Bioequivalence of methylphenidate hydrochloride of an extended release preparation; comparison of an intact capsule and an opened capsule sprinkled on applesauce*. *Int J Clin Pharm Ther*. 2006;44(3):135–41. doi:10.5414/CPP44135.

- Schütz H, Fischer R, Grossmann M, Mazur D, Leis HJ, Ammer R. *Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers*. *Int J Clin Pharm Ther*. 2009;47(12):761–9. doi:10.5414/CP47761.
- Leis HJ, Schütz H, Windischhofer W. *Quantitative determination of methylphenidate in plasma by gas chromatography negative ion chemical ionisation mass spectrometry using o-(pentafluorobenzoyloxy-carbonyl)-benzoyl derivatives*. *Anal Bioanal Chem*. 2011;400(8):2663–70. doi:10.1007/s00216-011-5048-6.
- Schütz H, Labes D, Fuglsang A. *Reference Datasets for 2-Treatment, 2-Sequence, 2-Period Bioequivalence Studies*. *AAPS J*. 2014;16(6):1292–7. doi:10.1208/s12248-014-9661-0.
- Roudier B, Davit B, Schütz H, Cardot J-M. *Impact of Data Base Structure in a Successful In Vitro-In Vivo Correlation for Pharmaceutical Products*. *AAPS J*. 2015;17(1):24–34. doi:10.1208/s12248-014-9680-x.
- Schütz H. *Two-stage designs in bioequivalence trials*. *Eur J Clin Pharm*. 2015;71(3):271–81. doi:10.1007/s00228-015-1806-2.
- Fuglsang A, Schütz H, Labes D. *Reference Datasets for Bioequivalence Trials in a 2-Group Parallel Design*. *AAPS J*. 2015;17(2):400–4. doi:10.1208/s12248-014-9704-6.
- Labes D, Schütz H. *Inflation of Type I Error in the Evaluation of Scaled Average Bioequivalence, and a Method for its Control*. *Pharm Res*. 2016;33(11):2805–14. doi:10.1007/s11095-016-2006-1.
- Cardot J-M, Roudier B, Schütz H. *Dissolution comparisons using a Multivariate Statistical Distance (MSD) test and a comparison of various approaches for calculating the measurements of dissolution profile comparison*. *AAPS J*. 2017;19(4):1091–1101. doi:10.1208/s12248-017-0063-y.
- Hermans C, Mahlangu J, Booth J, Schütz H, Santagostino E, Young G, Lee H-J, Steinitz-Trost KN, Blanchette V, Berntorp E. *Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII*. *Haemophilia*. 2018;24(3):376–84. doi:10.1111/hae.13483.
- Schütz H, Tomashevskiy M, Labes D, Shitova A, González-de la Parra M. *Reference Datasets for Studies in a Replicate Design intended for Average Bioequivalence with Expanding Limits*. In preparation 2018.
- Schütz H. *Group-Effects in Bioequivalence Studies*. In preparation 2018.

R packages

- Labes D, Schütz H, Lang B. *PowerTOST: Power and Sample Size Based on Two One-Sided t-Tests (TOST) for (Bio)Equivalence Studies*. 2018; R package version 1.4-7.
- Labes D, Lang B, Schütz H. *Power2Stage: Power and Sample-Size Distribution of 2-Stage Bioequivalence Studies*. 2018; R package version 0.5-1.
- Schütz H, Tomashevskiy M, Labes D. *replicateBE: Average Bioequivalence with Expanding Limits (ABEL)*. 2017; R package version 1.0-5.9000.
- Schütz H. *AdaptiveBE: Acceptability of Adaptive Bioequivalence Studies*. 2017; R package version 0.8-3.9000.